Standards Comparison

    PCI DSS

    Mandatory
    2022

    Global standard for protecting payment card data

    VS

    FDA 21 CFR Part 11

    Mandatory
    1997

    FDA regulation for trustworthy electronic records and signatures

    Quick Verdict

    PCI DSS secures payment card data for merchants worldwide via contractual controls, while FDA 21 CFR Part 11 ensures electronic records' trustworthiness for life sciences through validation and signatures. Companies adopt them to avoid fines, enable compliance, and build trust.

    Payment Security

    PCI DSS

    Payment Card Industry Data Security Standard

    Cost
    €€€€
    Complexity
    Medium
    Implementation Time
    6-12 months

    Key Features

    • 12 requirements organized into 6 control objectives
    • Over 300 granular sub-requirements with testing procedures
    • Contractual enforcement via fines and processing bans
    • Network segmentation to minimize CDE compliance scope
    • Quarterly ASV scans and annual penetration testing
    Electronic Records

    FDA 21 CFR Part 11

    21 CFR Part 11: Electronic Records; Electronic Signatures

    Cost
    €€€€
    Complexity
    High
    Implementation Time
    12-18 months

    Key Features

    • Secure time-stamped audit trails for record changes
    • Risk-based system validation and controls
    • Unique electronic signatures with non-repudiation
    • Access limitation and authority checks
    • Encryption and digital signatures for open systems

    Detailed Analysis

    A comprehensive look at the specific requirements, scope, and impact of each standard.

    PCI DSS Details

    What It Is

    PCI DSS (Payment Card Industry Data Security Standard) is an industry framework for securing cardholder data (CHD) and sensitive authentication data (SAD). Managed by the PCI Security Standards Council, it mandates technical and operational controls for organizations storing, processing, or transmitting payment card data. Its control-based approach focuses on protecting the cardholder data environment (CDE) through prescriptive requirements.

    Key Components

    • 12 requirements grouped into 6 control objectives (e.g., secure networks, vulnerability management, access controls).
    • Over 300 sub-requirements with detailed testing procedures.
    • Compliance via SAQs for smaller entities or ROCs by QSAs; includes quarterly ASV scans and annual penetration tests.

    Why Organizations Use It

    Contractually required for merchants/service providers; non-compliance risks fines, processing bans, and breach costs ($37/record avg.). Enhances fraud reduction, customer trust, and regulatory alignment (e.g., GDPR). Provides risk management and competitive edge in payments.

    Implementation Overview

    Phased: scope CDE, gap analysis, remediate controls, validate/attest. Applies globally to all card-handling entities; costs $5K-$200K+. Emphasizes segmentation, MFA, and ongoing monitoring. (178 words)

    FDA 21 CFR Part 11 Details

    What It Is

    21 CFR Part 11 is a US FDA regulation that sets criteria for electronic records and electronic signatures to be trustworthy, reliable, and equivalent to paper records and handwritten signatures. It governs FDA-regulated industries using electronic systems for predicate rule-required records. Adopts a narrow, risk-based scope per 2003 FDA guidance, focusing on reliance rather than all electronic data.

    Key Components

    • **Subpart BClosed (§11.10) and open (§11.30) system controls including validation, audit trails, access limits, operational/authority/device checks.
    • **Subpart CElectronic signatures with uniqueness (§11.100), manifestation (§11.50), linking (§11.70), multi-component controls (§11.200/300).
    • Core principles: authenticity, integrity, non-repudiation. No certification; compliance enforced via inspections.

    Why Organizations Use It

    • Legal compliance for electronic reliance in pharma, devices, biotech.
    • Mitigates data integrity risks, avoids warning letters.
    • Enables efficient digital operations, faster inspections.
    • Builds stakeholder trust, supports quality systems.

    Implementation Overview

    Phased risk-based approach: scope records, gap analysis, validation (IQ/OQ/PQ), controls, training, ongoing monitoring. Applies to mid-large FDA-regulated firms; US-centric, integrates with GxP.

    Key Differences

    Scope

    PCI DSS
    Protects cardholder data storage/processing/transmission
    FDA 21 CFR Part 11
    Ensures electronic records/signatures trustworthiness

    Industry

    PCI DSS
    Payment card merchants/service providers globally
    FDA 21 CFR Part 11
    Life sciences/pharma/medical devices US-regulated

    Nature

    PCI DSS
    Contractual security standard enforced by brands
    FDA 21 CFR Part 11
    FDA regulation with predicate rule enforcement

    Testing

    PCI DSS
    Quarterly ASV scans, annual QSA ROC/pentests
    FDA 21 CFR Part 11
    Risk-based CSV (IQ/OQ/PQ), audit trail validation

    Penalties

    PCI DSS
    Fines, processing bans, contractual enforcement
    FDA 21 CFR Part 11
    Warning letters, product holds, regulatory actions

    Frequently Asked Questions

    Common questions about PCI DSS and FDA 21 CFR Part 11

    PCI DSS FAQ

    FDA 21 CFR Part 11 FAQ

    You Might also be Interested in These Articles...

    Run Maturity Assessments with GRADUM

    Transform your compliance journey with our AI-powered assessment platform

    Assess your organization's maturity across multiple standards and regulations including ISO 27001, DORA, NIS2, NIST, GDPR, and hundreds more. Get actionable insights and track your progress with collaborative, AI-powered evaluations.

    100+ Standards & Regulations
    AI-Powered Insights
    Collaborative Assessments
    Actionable Recommendations

    Check out these other Gradum.io Standards Comparison Pages